Health AI Central
Peer-Reviewed Publication
Leukemia2026October 12, 2026Journal Article

PHI-101: a novel FLT3 inhibitor with potent activity against the F691L gatekeeper resistance mutation.

Marina Mitrou1, Li Li1, Bao Ho Nguyen1, Gi-Jun Sung2, Ky-Youb Nam2, Kyu-Tae Kim2, Jeong-Hyeok Yoon2, Michelle Wang1, David Young1,3, Ruiqi Zhu1,4, Tessa Seale1, Seung-Hye Choi5, Taebo Sim5,6,7,8, Donald Small9,10
1Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
2Pharos iBio Co. Ltd, Seoul, Republic of Korea.
3Translational Stem Cell Biology Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute (NHLBI), NIH, Bethesda, USA.
4Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
5Department of Medical Science, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Republic of Korea.
6Department of Biomedical Sciences, Yonsei University College of Medicine, Seoul, Republic of Korea.
7Graduate School of Clinical Drug Discovery & Development, Yonsei University College of Medicine, Seoul, Republic of Korea.
8Clinical Candidate Discovery & Development Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.
9Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. donsmall@jhmi.edu.
10Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA. donsmall@jhmi.edu.
PubMed DOI

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.